Lincoln Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+7.7%+9.6%
EBITDA−3.8%+3.1%
Net Income+6.7%+6.4%
EPS (adj.)+6.7%+6.4%
Total Assets+11.7%+14.9%
Total Equity+12.8%+14.7%
Free Cash Flow+8.6%+47.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LINCOLN₹558.10

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,118 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+7.7+9.6
EBITDA-3.8+3.1
Net Income+6.7+6.4
EPS (adj.)+6.7+6.4
Total Assets+11.7+14.9
Total Equity+12.8+14.7
Free Cash Flow+8.6+47.6
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.